Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
124.40    -1.80 (-1.43%)
Bid:
124.00
Ask:
124.20
Spread: 0.20 (0.161%)
Market Cap: £302.81m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
18th Aug 20257:00 amRNSNotice of Results
13th Aug 20255:12 pmRNS-RPRTC's Vedanta Announces VE202 Phase 2 Results
12th Aug 202512:00 pmRNS-RPRTC Launches Celea to Advance Ph3-Ready IPF Drug
5th Aug 20255:30 pmRNSHolding(s) in Company
1st Aug 20257:00 amRNSTotal Voting Rights
17th Jul 202512:05 pmRNS-RPRTC’s Seaport Begins Phase 2b Study in MDD
16th Jul 20257:00 amRNSPureTech Announces Leadership Transition
8th Jul 20255:45 pmRNSDirectorate Change
4th Jul 20255:30 pmRNSPDMR Notification
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20257:00 amRNS-RPRTC'S Vor Announces RemeGen License & $175M PIPE
16th Jun 20255:27 pmRNSResult of AGM
29th May 20255:30 pmRNSHolding(s) in Company
22nd May 202512:00 pmRNS-RPRTC to Present at Jefferies Healthcare Conference
21st May 20257:00 amRNS-RPRTC: IPF Data Support Lung Function Stabilization
9th May 202512:00 pmRNS-RPRTC Publishes Research on Unmet IPF Patient Needs
1st May 202512:00 pmRNS-RPRTC To Present Ph2b IPF Results at ATS Conference
30th Apr 20257:00 amRNSFinal Results
23rd Apr 20257:00 amRNSNotice of Results
11th Apr 20257:00 amRNSHolding(s) in Company
9th Apr 20253:00 pmRNSForm 8.3 PURETECH HEALTH PLC
9th Apr 20257:00 amRNS-RPRTC Appoints Peel Hunt Joint UK Corporate Broker
8th Apr 20252:53 pmGNWInvesco Ltd: Form 8.3 - PureTech Health PLC; Opening Position disclosure
8th Apr 20252:48 pmEQSForm 8.3 - The Vanguard Group, Inc.: PureTech Health plc
8th Apr 20251:15 pmRNSForm 8.3 -PURETECH HEALTH PLC
8th Apr 20251:10 pmRNSForm 8.3 PURETECH HEALTH PLC
8th Apr 202511:40 amGNWForm 8.3 - [PURETECH HEALTH PLC - Opening Disclosure - 07 04 2025] - (CGAML)
8th Apr 202510:00 amRNSForm 8.3 - Puretech Health plc
7th Apr 20255:22 pmRNSRule 2.8 Announcement
7th Apr 20254:27 pmRNSStatement re Possible Offer
11th Mar 202511:05 amRNS-RPRTC's Seaport Adds Finance/Operations Exec to BOD
3rd Mar 20257:00 amRNSTotal Voting Rights
27th Feb 20255:30 pmRNSPDMR Notification RSU Vesting
25th Feb 202512:00 pmRNS-RPRTC Presents at Leerink Partners Healthcare Conf
12th Feb 202512:05 pmRNS-RPRTC's Seaport Publishes New Glyph Platform Data
27th Jan 20257:00 amRNS-RPRTC's Vedanta Publishes Ph2 in Nature Medicine
8th Jan 202512:00 pmRNS-RPureTech to Present at the JP Morgan Conference
6th Jan 20257:00 amRNS-RPureTech Appoints UBS as UK Corporate Broker
16th Dec 20247:00 amRNSPRTC's Ph2b in IPF Successful; New SOC Potential
11th Dec 20245:30 pmRNSHolding(s) in Company
27th Nov 20245:31 pmRNSHolding(s) in Company
27th Nov 20245:30 pmRNSHolding(s) in Company
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 20245:00 pmRNSDirector/PDMR Shareholding
21st Oct 20247:00 amRNSPRTC's Seaport Closes $225M Series B Financing
27th Sep 20247:00 amRNSKarXT/Cobenfy Approved by FDA; PRTC Receives $29M
6th Sep 20246:13 pmRNSHolding(s) in Company
28th Aug 20247:01 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.